Akut miyeloid lösemide FLT3 mutasyonlarının prognozuna ve diğer genetik değişikliklerle etkileşimlerine genel bakış

Year 2024, Volume: 14 Issue: 4, 433 - 434, 31.12.2024

Aynur Dağlar Aday , Ayşe Gül Bayrak Tokaç

https://doi.org/10.31832/smj.1595597

Abstract

Acute Myeloid Leukemia (AML) is one of the most aggressive hematological malignancies. It has a highly heterogeneous genetic background and complex clonal evolution. In this letter, we emphasized the prognostic importance of a crucial biomarker in acute myeloid leukemia (AML) – the Fms - like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase that plays a significant role in several cellular signalling processes. FLT3 is found on hematopoietic stem cells and early progenitor cells. After binding to its ligand, activated FLT3 triggers intracellular kinase, leads to cellular proliferation, and inhibits differentiation and apoptosis.

Keywords

FLT3, mutasyon, akut myeloid lösemi

Overview of Prognosis of FLT3 Mutations and Interactions with Other Genetic Alterations in Acute Myeloid Leukemia

Abstract

Acute Myeloid Leukemia (AML) is one of the most aggressive hematological malignancies. It has a highly heterogeneous genetic background and complex clonal evolution. In this letter, we emphasized the prognostic importance of a crucial biomarker in acute myeloid leukemia (AML) – the Fms - like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase that plays a significant role in several cellular signalling processes. FLT3 is found on hematopoietic stem cells and early progenitor cells. After binding to its ligand, activated FLT3 triggers intracellular kinase, leads to cellular proliferation, and inhibits differentiation and apoptosis.

Keywords

FLT3, mutation, acute myeloid leukemia

References

• Kennedy VE, Smith CC. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Front Oncol. 2020 Dec 23;10:612880. doi: 10.3389/fonc.2020.612880. PMID: 33425766; PMCID: PMC7787101.
• Negotei C, Colita A, Mitu I, Lupu AR, Lapadat ME, Popovici CE, et. al. A Review of FLT3 Kinase Inhibitors in AML. J Clin Med. 2023 Oct 10;12(20):6429. doi: 10.3390/jcm12206429. PMID: 37892567; PMCID: PMC10607239.
• Reikvam H. Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia. Expert Rev Hematol. 2023 May;16(5):317-323. doi: 10.1080/17474086.2023.2202849. Epub 2023 Apr 17. PMID: 37066885.
• Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et. al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PMID: 35797463.
• Christen F, Hoyer K, Yoshida K, Hou HA, Waldhueter N, Heuser M, et. al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): An international study on 331 patients. Blood. 2019 Mar 7;133(10):1140-1151. doi: 10.1182/blood-2018-05-852822. Epub 2019 Jan 4. PMID: 30610028.